American

American Gene Technologies (AGT) is a clinical-stage biotechnology company specializing in the development of gene and cell therapies for infectious diseases, monogenic disorders, and cancer. The company's primary focus is its HIV cure program, which utilizes a proprietary lentiviral vector platform to create HIV-resistant T cells. Beyond infectious disease, AGT is advancing programs for Phenylketonuria (PKU) and immuno-oncology, leveraging its ability to modify the immune system at the genetic level. Headquartered in Rockville, Maryland, the company aims to transform chronic treatments into one-time curative interventions through advanced genetic engineering.